147 related articles for article (PubMed ID: 18574651)
21. Administration of voriconazole in patients with renal dysfunction.
Neofytos D; Lombardi LR; Shields RK; Ostrander D; Warren L; Nguyen MH; Thompson CB; Marr KA
Clin Infect Dis; 2012 Apr; 54(7):913-21. PubMed ID: 22267716
[TBL] [Abstract][Full Text] [Related]
22. Editorial commentary: Antifungal therapeutic drug monitoring progress: getting it right the first time.
Andes D; Lepak A
Clin Infect Dis; 2012 Aug; 55(3):391-3. PubMed ID: 22610924
[No Abstract] [Full Text] [Related]
23. Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole.
Frick MA; Soler-Palacín P; Martín Nalda A; Guarner ME; Nadal CF
Pediatr Infect Dis J; 2010 May; 29(5):480-1. PubMed ID: 20431387
[No Abstract] [Full Text] [Related]
24. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
[TBL] [Abstract][Full Text] [Related]
26. Voriconazole-associated severe hyponatremia.
Kim KH; Lee S; Lee S; Yun NR; Kim NJ; Yu KS; Jang IJ; Park WB; Oh MD
Med Mycol; 2012 Jan; 50(1):103-5. PubMed ID: 21671829
[TBL] [Abstract][Full Text] [Related]
27. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.
Levin MD; den Hollander JG; van der Holt B; Rijnders BJ; van Vliet M; Sonneveld P; van Schaik RH
J Antimicrob Chemother; 2007 Nov; 60(5):1104-7. PubMed ID: 17827141
[TBL] [Abstract][Full Text] [Related]
28. Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction.
Spriet I; Grootaert V; Meyfroidt G; Debaveye Y; Willems L
Eur J Clin Pharmacol; 2013 Mar; 69(3):737-8. PubMed ID: 22878691
[No Abstract] [Full Text] [Related]
29. Hallucinations during voriconazole therapy: who is at higher risk and could benefit from therapeutic drug monitoring?
Pea F; Viale P
Ther Drug Monit; 2009 Feb; 31(1):135-6. PubMed ID: 19077926
[No Abstract] [Full Text] [Related]
30. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
[TBL] [Abstract][Full Text] [Related]
31. Successful management of voriconazole-associated hyponatremia with therapeutic drug monitoring.
Xu RA; Lin GY; Hu LF; Shi DW; Ye XL; Liu YJ; Pan XF; Zhang CH; Zhang XH
Antimicrob Agents Chemother; 2013 May; 57(5):2422-3. PubMed ID: 23403435
[No Abstract] [Full Text] [Related]
32. An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole.
Jacobs F; Selleslag D; Aoun M; Sonet A; Gadisseur A
Eur J Clin Microbiol Infect Dis; 2012 Jun; 31(6):1173-9. PubMed ID: 21971820
[TBL] [Abstract][Full Text] [Related]
33. Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database.
Kato H; Shiraishi C; Hagihara M; Mikamo H; Iwamoto T
Sci Rep; 2024 May; 14(1):12519. PubMed ID: 38822123
[TBL] [Abstract][Full Text] [Related]
34. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.
den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD
J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632
[TBL] [Abstract][Full Text] [Related]
35. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
36. Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial.
Mootsikapun P; Hsueh PR; Talwar D; Co VM; Rajadhyaksha V; Ong ML
BMC Infect Dis; 2013 May; 13():219. PubMed ID: 23676114
[TBL] [Abstract][Full Text] [Related]
37. Adverse reactions to voriconazole.
Boyd AE; Modi S; Howard SJ; Moore CB; Keevil BG; Denning DW
Clin Infect Dis; 2004 Oct; 39(8):1241-4. PubMed ID: 15486850
[TBL] [Abstract][Full Text] [Related]
38. Safety of voriconazole and dose individualization.
Lutsar I; Hodges MR; Tomaszewski K; Troke PF; Wood ND
Clin Infect Dis; 2003 Apr; 36(8):1087-8. PubMed ID: 12684928
[No Abstract] [Full Text] [Related]
39. Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles.
Thompson GR; Bays D; Cohen SH; Pappagianis D
Antimicrob Agents Chemother; 2012 Jan; 56(1):563-4. PubMed ID: 22005993
[TBL] [Abstract][Full Text] [Related]
40. Hallucinations during voriconazole therapy.
Zonios DI; Gea-Banacloche J; Childs R; Bennett JE
Clin Infect Dis; 2008 Jul; 47(1):e7-e10. PubMed ID: 18491963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
